News | September 03, 2008

Six-Year Follow-up Data Confirms Endologix Powerlink’s Outstanding Durability and Outcomes

September 3, 2008 - Endologix Inc. yesterday said six-year patient follow-up data from the company’s Powerlink System pivotal clinical trial supporting the durability of the Powerlink System as a minimally invasive treatment for abdominal aortic aneurysm (AAA) and was published in the Journal of Vascular Surgery (September 2008).

Highlights from the six-year follow-up of patients treated with the Powerlink System include a 97.9 percent freedom from AAA mortality. The device also had excellent device performance and integrity, with no ePTFE graft failures, no stent fractures, or aneurysm ruptures. The study results also showed low incidence of secondary procedures to treat Type I endoleak (3.1 percent) or a limb occlusion (1.6 percent). There was also a significant aneurysm sac diameter reduction in 83 percent of patients.

For more information: www.endologix.com

Related Content

ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study| June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study| August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init